NASDAQ · STOCK
Bristol Myers Squibb
$65.30
52W $42.52 – $65.66
56/100
$133.37B
14.4
0.23
Is BMY Bullish or Bearish?
Mixed.
Innellis AI committee rates Bristol Myers Squibb (BMY) Watch with a composite score of 56/100
, based on 7 analysts with 43% agreement.
Last updated August 01, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.83 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.17 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 26.3% yoy. Risk Analyst remains cautious — high leverage (debt-to-equity 2.44) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 41.6% shows genuine earnings power backing the valuation — Value
- Dividend yield of 3.9% pays you to wait — Value
- EPS growing 26.3% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Debt-to-equity of 2.44 adds balance-sheet risk to the value case — Value
- RSI at 80 is in overbought territory — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- High leverage (debt-to-equity 2.44) amplifies downside in a stress scenario — Risk
- Bollinger bandwidth of 17.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 01, 2026
Overall Committee Score
56/100
Agreement
43%
Analysts
7
Conviction
Contested
Sector Rank
Top 59%
of 93 Healthcare peers
Value Analyst
neutral
50
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 41.6% shows genuine earnings power backing the valuation
− Price-to-book of 5.9x prices in significant intangible value
Growth Analyst
bullish
72
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 26.3% YoY
Technical Analyst
neutral
57
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 80 is in overbought territory
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.44) amplifies downside in a stress scenario
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 107 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2535.03)
Investment Thesis Evolution
Committee score moved marginally from 57.9 to 56.2.
- Committee agreement fell modestly from 50% to 43%.
- New bearish signals: 7 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 4 appeared.
- Bearish pressure eased: 5 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
- New analyst(s) joined: Value Analyst.
Analyst-level changes:
- Growth Analyst: score 82->72 (-10); +1 bullish signal(s).
- Macro Analyst: stance neutral->bullish; score 58->70 (+12).
- News Analyst: score 70->66 (-4); +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Risk Analyst: +2 bearish signal(s).
- Technical Analyst: +1 bearish signal(s).
- Value Analyst joined: neutral at 50.
Comparing 2026-07-31 to 2026-08-01 (1 day apart).
Technical Analysis
RSI (14)
79.6
Overbought
MACD Histogram
0.480
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$63.22
Resistance
$66.22
Bollinger %B
0.97
Inside Bands
Price vs Moving Averages
EMA 9
$62.98
Above
EMA 21
$60.98
Above
EMA 50
$59.18
Above
EMA 200
$56.22
Above
Fundamental Analysis
Valuation
77
Growth
87
Profitability
1
Financial Health
45
Cash Flow
37
Valuation
P/E Ratio
14.4×
P/B Ratio
5.98×
PEG Ratio
0.17
Dividend Yield
0.04%
52W High
$65.66
52W Low
$42.52
Quality & Growth
ROE
38.2%
ROA
7.8%
Gross Margin
70.2%
Operating Margin
28.3%
Revenue Growth YoY
—
Debt / Equity
1.93
AI Fundamental Assessment
P/E ratio of 14.4 (inexpensive relative to a 15-40x range); Price-to-book of 6.0x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.4%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.7%; Current ratio of 1.53 (healthy short-term liquidity); Debt-to-equity of 1.93; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (6.02); Most recent quarter beat estimates by 27.2%; 5 consecutive earnings beats; EPS growth accelerating (+25.4% -> +29.1% QoQ); Average YoY EPS growth of 39.7%; Analyst estimates rising over recent quarters
Get the Full BMY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →